Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Genetown save search
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
PHGE | $0.3465 17.42% 1.01% 220K
|
Health Technology
|
| O: 6.03%
H: 0.0%
C: 0.0%
bx004 treatment fibrosis for study
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.09%
H: 0.0%
C: 0.0%
lung approval cancer cell treatment for
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
SYRS | $5.17 3.61% 3.48% 170K
|
Health Technology
|
| O: 2.16%
H: 23.21%
C: 16.03%
fda treatment designation for aml
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
STOK | $11.24 -0.09% -0.09% 600K
|
Health Technology
|
| O: -0.16%
H: 8.11%
C: 3.34%
stk-001 first treatment therapeutics potential
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-21 (Crawled : 21:00) - biospace.com/
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
|
| O: 0.85%
H: 0.88%
C: 0.02%
vx-407 fda drug disease kidney treatment clearance application
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
KALV | News | $11.21 -2.01% -2.05% 190K
|
Health Technology
|
| O: -0.08%
H: 3.61%
C: 0.59%
conference treatment pharmaceuticals
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
fda brukinsa approval treatment
Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy
Published: 2024-03-04 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
opl-0401 health treatment study diabetic
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-02-26 (Crawled : 11:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
lung chmp positive cancer cell treatment
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.07%
H: 0.46%
C: 0.42%
fda first treatment
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
Published: 2024-01-18 (Crawled : 23:00) - biospace.com/
VSTM | $9.58 -1.64% -1.67% 100K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.48%
lung avutometinib granted cancer cell treatment designation
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 2.05%
H: 0.29%
C: 0.0%
livtencity approval cytomegalovirus treatment china
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2023-12-15 (Crawled : 22:00) - biospace.com/
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
|
| O: 0.38%
H: 0.84%
C: 0.62%
first disease chmp positive cell treatment
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Published: 2023-11-29 (Crawled : 20:00) - biospace.com/
PTCHF | $2.61 19.97% 4.1K
|
n/a
|
| O: -1.0%
H: 1.01%
C: -2.27%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.74%
H: 3.66%
C: 0.99%
drug food treatment schizophrenia application therapeutics
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Published: 2023-11-27 (Crawled : 23:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450K
|
Health Technology
|
| O: -1.19%
H: 5.2%
C: 4.8%
reproxalap drug disease food treatment eye application therapeutics response
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
Published: 2023-10-25 (Crawled : 13:00) - biospace.com/
AKBA | $1.365 0.37% 0.37% 2.1M
|
Health Technology
|
| O: -0.82%
H: 3.51%
C: -5.88%
fda disease kidney resubmission anemia treatment
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Published: 2023-10-18 (Crawled : 22:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -1.61%
H: 0.14%
C: -0.27%
cd30 adcetris treatment
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGAStudy showed a 70% Inhibition of Recurrent Tumor Growth
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
RNAZ | $0.461 0.44% 0.43% 100K
|
Professional, Scientific, and T...
|
| O: 14.24%
H: 7.44%
C: -7.36%
melanoma tumors treatment tumor preclinical immunotherapy therapeutics growth
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
Published: 2023-10-13 (Crawled : 00:20) - biospace.com/
AMLX A | $1.945 -1.77% -1.8% 1.5M
|
|
| O: -3.75%
H: 2.83%
C: 2.18%
amx0035 chmp als treatment pharmaceuticals application negative
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-10-09 (Crawled : 14:30) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -4.06%
H: 2.17%
C: -0.83%
fda drug treatment application response
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.